How Does Early Pregnancy Lower Breast Cancer Risk? Odd Cells Could Offer Clues
Researchers reported in Nature Communications that early pregnancy prevents the accumulation of a novel hybrid mammary cell type in mice. These cells, which produce the inflammatory cytokine IL33, increase with age in never‑pregnant females and are linked to tissue changes associated with cancer. Injecting IL33 into young mice recreated the hybrid‑cell phenotype, suggesting a causal role. The findings offer a potential cellular explanation for the long‑observed protective effect of early childbirth on breast‑cancer risk.
Genomics Delegation to Boston – June 2026
The Canadian Genomics Strategy Secretariat, Global Affairs Canada and Genome Canada are organizing a genomics trade mission to Boston during the first week of June 2026, coinciding with the Festival of Genomics, Biodata and Artificial Intelligence. Selected Canadian genomics firms...
A Noble Pursuit: A Long-Time AI-in-Biotech Skeptic Takes Another Look
Tim Harris, a veteran biotech investor, revisits his skepticism about artificial intelligence in drug discovery, noting the surge of AI‑focused startups and sizable funding rounds. He outlines how AI is being applied to molecular dynamics, protein‑protein interaction prediction, and antibody...
Bridging Innovation and Clinical Reality: Shalabh Gupta, CEO of Unicycive Therapeutics, on the Future of Biotech
Shalabh Gupta, CEO of Unicycive Therapeutics, argues that biotech can benefit from tech‑driven design thinking, rapid prototyping, and disciplined capital allocation. He highlights how the company repurposed automotive battery‑shrinkage technology to create Oxylanthanum carbonate, a kidney‑disease candidate now under FDA...
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
Xenon Pharmaceuticals reported that its Phase 3 X‑TOLE2 trial of azetukalner, a novel Kv7 potassium channel opener, achieved a 53.2% reduction in focal onset seizures at the 25 mg dose, far exceeding expectations and representing the highest placebo‑adjusted efficacy recorded in a...
Genome Editing for Biopharmaceutical Manufacturing
Chinese hamster ovary (CHO) cells remain the backbone of biopharmaceutical manufacturing, but traditional gene‑editing tools struggle with low knock‑in efficiency. Transposase‑based platforms such as Leap‑In and piggyBac now provide high‑efficiency, multi‑copy integration and can handle large DNA cargos up to...
Op-Ed | A Toxic Turn for Our Daily Bread: Why GMO Wheat Raises Serious Concerns
The U.S. government has approved HB4, a genetically engineered wheat tolerant to the herbicide glufosinate, marking the first commercial GMO wheat in America. Glufosinate is linked to reproductive toxicity and is banned in the EU, raising concerns about residue buildup...
RNA Editing Startup Tacit Therapeutics Launches with $19M for Brain Diseases
Tacit Therapeutics, an RNA‑editing startup focused on neurological disorders, announced its launch backed by a $19 million financing round. The capital, led by Andreessen Horowitz and DCVC, will fund the development of ADAR‑based therapeutics targeting diseases such as ALS, Huntington’s, and...
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
The FDA’s Oncologic Drugs Advisory Committee will convene on April 30 to evaluate AstraZeneca’s oral SERD camizestrant for first‑line HR‑positive, HER2‑negative breast cancer and its AKT inhibitor Truqap for metastatic hormone‑sensitive prostate cancer. Camizestrant’s Phase 3 SERENA‑6 trial reported a 56% reduction...
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
The FDA rejected Incyte’s supplemental application to add non‑small cell lung cancer to Zynyz’s label, citing compliance failures at Novo Nordisk’s Catalent‑owned Indiana manufacturing plant. The agency’s complete response letter pinpointed inspection findings at the site as the sole approvability...
The First KRAS Drugs Have Been Sluggish on the Market. Will the Next Generation Fare Better?
Amgen’s Lumakras earned accelerated FDA approval in 2021 as the first KRAS‑targeted therapy, but sales have been modest, reaching $92 million in Q4 2025 with only an 8% year‑over‑year increase. A second G12C inhibitor, Krazati, entered the market in 2022, narrowing Amgen’s...
Roche's Oral SERD Flunks Phase 3 Breast Cancer Test
Roche’s oral SERD giredestrant failed to meet its primary endpoint in the phase 3 persevERA trial, showing no significant improvement over letrozole when combined with palbociclib in first‑line HR‑positive, HER2‑negative advanced breast cancer. The company now limits U.S. filing to ESR1‑mutated...
Photothermally Triggered Intratumoral In Situ Drug Synthesis: A Smart Nanoplatform for NIR‐Controlled Precise Activation of Antitumor Precursors
Researchers have engineered an iron‑doped mesoporous silica nanoplatform (FOBA) that, when exposed to 808 nm near‑infrared light, uses the Y6 photothermal converter to heat and trigger a PEG gate, creating a transient solvent that enables in‑situ synthesis of the cytotoxic agent...
A Recyclable Magnetic Nanosystem Enable Circulatory Antibacterial Strategy for Static and Dynamic Blood Disinfection
Researchers have engineered a recyclable magnetic nanosystem (Fe3O4/CeO2@BP) that integrates black phosphorus with iron oxide and cerium oxide to achieve rapid, ROS‑driven antibacterial activity in blood. The material can be magnetically retrieved, enabling repeated use across at least 20 disinfection...
LifeVac Receives FDA De Novo Classification for Anti-Choking Device
LifeVac has secured FDA De Novo classification, designating its suction anti‑choking device as a Class II medical device for second‑line treatment after failed basic life support protocols. The clearance confirms the device as a single‑use, non‑powered, non‑invasive tool suitable for adults and...
Aisa Pharma Reports Positive Results for AISA-021
Aisa Pharma announced positive Phase II data for AISA‑021, a once‑daily calcium channel blocker, in systemic sclerosis‑associated Raynaud’s phenomenon (SSc RP). The double‑blind, placebo‑controlled RECONNOITER trial enrolled 64 patients and showed a 22.1% reduction in weekly Raynaud attacks and a 155% placebo‑adjusted...
Blood Test Using P-Tau217 Biomarker Predicts Alzheimer’s Symptom Onset Within 3–4 Years
Researchers at Washington University have created a blood‑test model using plasma p‑tau217 that can predict the onset of Alzheimer’s symptoms within three to four years. The model, validated on 603 participants, shows age‑dependent timelines, with younger individuals experiencing longer asymptomatic...
Health Care Interests Take Shape Ahead of State Budget Negotiations
Health care stakeholders in New York are mobilizing as the state budget negotiations intensify, with the Associated Medical Schools of New York lobbying for an additional $100 million to bolster biomedical research and life‑science jobs. The state already receives over $3.5 billion...
Safety Concerns Prompt Ipsen to Pull Tazverik From Market
Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik worldwide after an interim safety analysis in the phase 1b/3 SYMPHONY‑1 trial linked the drug to secondary hematologic malignancies. The pull‑back includes terminating all ongoing Tazverik studies and recalling the product in markets...
Navigating the PPQ Process: Proven Strategies to Safeguard Quality for Cell and Gene Therapies
Process Performance Qualification (PPQ) is the final validation step before commercial manufacturing of cell and gene therapies, but its complexity often triggers delays and compliance risks. The article highlights three proven strategies—early master‑plan development, continuous quality improvement, and data‑driven analytics—to...
Roche’s Big-Hope Breast Cancer Drug Fails in Crucial First-Line Trial
Roche’s oral breast‑cancer therapy, touted as a potential blockbuster, missed its primary endpoint in the pivotal Phase 3 persevERA trial. The study evaluated the drug as a first‑line treatment for hormone‑receptor‑positive, HER2‑negative metastatic breast cancer and enrolled more than 1,200 patients...
kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics
Kyron.bio announced a strategic partnership with Servier to glycoengineer a Servier‑selected antibody using its precision glycosylation platform. Servier will fund the research and retain an option to pursue further development based on the results. The collaboration builds on Kyron.bio’s 2024...
Under Trump, mRNA Skepticism Threatens a Promising Technology
Under the Trump administration, the U.S. government slashed nearly $500 million in mRNA research funding, canceling 22 projects and a $766 million Moderna contract. The FDA’s initial refusal then reversal to review Moderna’s flu vaccine highlighted regulatory skepticism toward the platform. Private‑sector...
A Coding Guide to Build a Complete Single Cell RNA Sequencing Analysis Pipeline Using Scanpy for Clustering Visualization and Cell...
The article presents a step‑by‑step Python tutorial that builds a full single‑cell RNA‑sequencing (scRNA‑seq) analysis pipeline using Scanpy. It walks through data loading, quality‑control filtering, normalization, highly variable gene selection, PCA, neighbor‑graph construction, UMAP embedding, Leiden clustering, and marker‑gene based...
Arq Inc (ARQ) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics reported record Q4 2025 results, with net product revenue of $127.5 million, an 84% year‑over‑year increase, and full‑year revenue up 123% to $372.1 million. Management raised its 2026 net product revenue guidance to $480‑$495 million, citing strong prescription growth, expanded Medicare...
Logic‑gated Nanomedicine Activates STING to Boost Metastatic Tumour Immunotherapy
Researchers at the University of Massachusetts Amherst have engineered a logic‑gated nanoparticle that releases a STING agonist only under acidic pH and hypoxic conditions typical of metastatic tumor sites. The dual‑stimuli‑responsive system triggers robust innate immune activation while sparing healthy...
How Fast Does a Protein Fold? Real-Time Technique Captures the Moment
Scientists have directly measured the transition‑path time of protein folding using an enhanced single‑molecule fluorescence technique. By attaching donor and acceptor dyes to opposite ends of a protein chain and amplifying the signal with nanoscale wells, they captured folding events...
Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Transcript
Zevra Therapeutics reported Q3 2025 net revenue of $26.1 million, driven primarily by $22.4 million from its FDA‑approved NPC therapy MyPlayFa. The company narrowed its net loss to $0.5 million, a dramatic improvement from a $33.2 million loss a year earlier, while cash and...
Editas Medicine Inc (EDIT) Q4 2025 Earnings Call Transcript
Editas Medicine reported Q2 2024 progress on its gene‑edited cell therapy reni‑cel, presenting interim data from the RUBY sickle‑cell and EdiTHAL beta‑thalassemia trials. All 18 RUBY patients were free of vaso‑occlusive events, with hemoglobin levels above 14 g/dL and fetal hemoglobin exceeding...
AND Logic Nanoparticle for Precision Immunotherapy of Metastatic Cancers
Researchers have engineered a dual‑stimuli‑responsive nanoparticle that activates the STING pathway only when both acidic pH and hypoxic NQO1 activity are present, creating an AND‑logic release of the agonist MSA‑2. In preclinical models of lung carcinoma, triple‑negative breast cancer and...
Anixa Biosciences Inc (ANIX) Q1 2026 Earnings Call Transcript
Anixa Biosciences reported $131.7 million in cash, no debt, and a cash burn of $7.1 million in Q1 2026, extending its runway to over three years. Operating expenses fell sharply, with R&D down 55% YoY and G&A reduced by 32%, reflecting the end...
MacroGenics Inc (MGNX) Q4 2025 Earnings Call Transcript
MacroGenics reported 2024 revenue of $150 million, up from $58.7 million, largely fueled by $85 million in milestone payments from its Incyte partnership. The company posted a net loss of $67 million versus $9.1 million a year earlier, while cash and marketable securities fell to...
Deciphering the Causal Influence of BMI and Related Metabolic, Inflammatory, and Cardiovascular Factors on Brain Structure: A Mendelian Randomization Study
The study applied univariate and multivariate Mendelian randomization to test whether body mass index (BMI) causally influences brain structure. Results indicate that genetically higher BMI leads to reduced cortical thickness, especially in the precentral and fusiform gyri. Visceral adipose tissue...
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
The FDA has issued a final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.” The document outlines the agency’s scientific framework for establishing biosimilarity of therapeutic proteins submitted via the abbreviated licensure pathway. It details expectations for...
A Single Dose of DMT Reverses Depression-Like Symptoms in Mice by Repairing Brain Circuitry
Researchers at Uppsala University reported that a single 30 mg/kg injection of the psychedelic N,N‑dimethyltryptamine (DMT) reversed depression‑like behaviors in mice subjected to chronic stress. The treated animals recovered their preference for sweetened water, displayed improved working‑memory performance, and showed reduced...
High-Throughput Hidden Antibiotic Resistance Detection Unveiled
A study by Ma and Kim in Nature Communications unveils the dilution‑and‑delay (DnD) susceptibility assay, a high‑resolution, high‑throughput method that combines antibiotic dilution gradients with timed incubation delays. Leveraging microfluidic chips and real‑time imaging, the assay can screen thousands of...
Chocolate Company Announces Plans to Produce Lab-Grown Cocoa
Puratos and California Cultured announced a partnership to develop commercially viable lab‑grown cocoa, aiming for a market‑ready product by the end of 2026. The process cultivates cocoa cells from elite flavor samples, shrinking growth time to days once scale is...
'It Could Revolutionize, Completely, the Way We Treat Depression': Researchers Are Exploring Promising Immune Therapy for Treating Psychiatric Symptoms
Researchers led by Dr. James Murrough and Dr. Emma Guttman‑Yassky identified the Th2 immune pathway as a contributor to major depressive disorder. Using proteomic profiling and computer modeling, they repurposed dupilumab—an IL‑4 receptor antibody approved for eczema—to target this pathway....
HIV-Seq Tool Finds Active Reservoir Cells During Therapy
A team at Gladstone Institutes and the San Francisco VA has launched HIV‑seq, a virus‑specific single‑cell RNA‑sequencing platform that isolates active HIV reservoir cells from patients on antiretroviral therapy (ART). The method captured 25 treated‑patient cells and over 1,000 cells from...
Machine Learning Links DEHP and Sjögren’s Immune Signatures
Researchers combined network toxicology, machine‑learning models and SHAP interpretability to show that exposure to the plasticizer Di(2‑ethylhexyl) phthalate (DEHP) generates immune signatures overlapping with Sjögren’s syndrome. By mapping thousands of DEHP‑associated genes, proteins and metabolites, they identified shared pathways involving...
The Age of Animal Experiments May Be Waning
Governments in the UK, US and EU are committing to phase out animal testing, starting with skin‑irritation assays and targeting broader reductions by 2030. Rapid advances in new‑approach methodologies—organs‑on‑chips, organoids and AI‑driven computational models—have driven a fourfold rise in NAM‑only...
Lysophosphatidylcholine Acyltransferase 1 Drives Cancer via COX17
Researchers have identified lysophosphatidylcholine acyltransferase 1 (LPCAT1) as a driver of head and neck squamous cell carcinoma (HNSCC) by amplifying mitochondrial oxidative phosphorylation through the COX17 chaperone. Overexpression of LPCAT1 reshapes mitochondrial membrane lipids, stabilizing COX17 and boosting cytochrome c oxidase activity,...
ITK-Targeting Boosts Anti-CD19 CAR-T Therapy
A recent preclinical study shows that inhibiting interleukin‑2‑inducible T‑cell kinase (ITK) markedly improves the efficacy of anti‑CD19 CAR‑T cells. Researchers combined an ITK‑selective inhibitor with a second‑generation CD19‑CAR construct, observing enhanced cytotoxicity, reduced exhaustion markers, and prolonged persistence in mouse...
![[Comment] Aldosterone Synthase Inhibition in Resistant Hypertension: Promises and Unknowns](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/0a5065acfb3787a2e2e6999bae6248e9.webp)
[Comment] Aldosterone Synthase Inhibition in Resistant Hypertension: Promises and Unknowns
Resistant hypertension affects up to 20 % of hypertensive patients and carries heightened cardiovascular risk. Recent phase‑3 studies of aldosterone synthase inhibitors such as baxdrostat and lorundrostat have demonstrated significant ambulatory blood‑pressure reductions, positioning them as potential fourth‑line agents beyond traditional...
Prasad Out At FDA, Turning Critics’ Focus Back To Makary
Vinay Prasad, the FDA’s controversial biologics chief, has announced his departure, marking his second exit within a year. His resignation follows a public dispute over the agency’s handling of rare disease drug approvals, intensifying scrutiny of FDA decision‑making. Critics are...
High Fat, Low- Carb Diet Lowers Blood Sugar, Improves Exercise Response in Mice
A mouse study found that a high‑fat, low‑carb ketogenic diet normalized blood‑sugar levels in hyperglycemic mice and, when combined with aerobic training, restored their peak oxygen consumption (VO2max). The diet shifted metabolism toward fatty‑acid oxidation and ketone utilization, eliminating muscle‑remodeling...
EBay Is Selling a Cornucopia of Russian Peptides
A quick search on eBay reveals a flood of Russian‑origin peptide products, from injectable ampoules to dubious oral supplements. The items, marketed by Vita Stream Inc. – a firm linked to former footballer Roman Eremenko – claim bioregulation benefits but...
As Peptides Go Mainstream, USP and Matter More Than Ever
Peptide therapies have moved from niche compounding to mainstream outpatient care, driven by telehealth platforms and rapid market growth. This expansion has attracted regulatory attention, with state boards and courts increasingly referencing USP and as compliance benchmarks. Non‑sterile peptide...
Simultaneously Decoding the Transcriptome, Epigenome and 3D Genome Within a Single Cell
The team led by Inkyung Jung and Yarui Diao introduced scHiCAR, a trimodal single‑cell technology that simultaneously captures transcriptome, epigenome, and 3D genome architecture. By integrating AI, the method achieves ultra‑high throughput at roughly $0.04 per cell and was used...
5 FDA Developments From February: Kinase Inhibitors, GLP-1s, and a New Approval Pathway
In February 2026 the FDA approved a suite of targeted therapies, including the HER2‑mutant NSCLC kinase inhibitor zognertinib and the first all‑oral acalabrutinib‑venetoclax combo for CLL/SLL, as well as a BRAF‑targeted encorafenib regimen for metastatic colorectal cancer. A portable tumor‑treating‑fields...
